Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA32459 in advanced malignancies
NCT05577182Phase 1Completed
- Sponsor
- Incyte
- Start
- Jan 2023
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of INCA32459 in melanoma and squamous cell carcinoma of the head and neck (HNSCC) (3 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities at 12 months, Treatment Emergent Adverse Events at 12 months and 2 more. Started Jan 2023; status: completed.
02
Drugs
INCA32459
03
Conditions
melanomasquamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05577182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577182.